Tesamorelin

Tesamorelin 5 mg - Premium Research Peptide | PeptideHubs What is Tesamorelin? Overview In the fields of growth hormone axis regulation, metabolic disorder intervention, and anti-aging research, a synthetic peptide derived from endogenous growth hormone-releasing hormone (GHRH) and possessing both potent growth hormone secretion-promoting and metabolic regulation properties is becoming a research hotspot—Tesamorelin. Developed by Theratechnologies in Canada, this structurally optimized human growth hormone-releasing hormone (GHRH) analogue's core advantage lies in its precise targeting of pituitary GHRH receptors. By stimulating the pulsatile secretion of endogenous growth hormone (GH), it achieves four effects: metabolic regulation, visceral fat reduction, muscle mass maintenance, and neuroprotection. Furthermore, its N-terminal structural modification significantly enhances its stability, avoiding the limitations of natural GHRH, such as easy enzymatic degradation and short duration of action. Like a "precise regulator of the growth hormone axis," it plays an irreplaceable role in research related to HIV-related lipodystrophy, obesity, metabolic syndrome, and neurodegenerative diseases.

The unique advantage of this peptide lies in its perfect balance between "physiological pulsatile secretion" and "long-lasting stability." Compared to the limitations of natural GHRH (44 amino acids), which has an extremely short half-life (only a few minutes) and is easily degraded by proteases such as dipeptidyl peptidase-4 (DPP-4), Tesamorelin, through N-terminal structural modification, extends the in vivo half-life to 26-38 minutes and increases bioavailability to 4%-7%. It can continuously stimulate the pituitary gland to secrete GH and can mimic the pulsatile release pattern of GH under physiological conditions, avoiding non-physiological sustained increases caused by exogenous GH administration and reducing adverse reactions. At the same time, as a full-length GHRH analog, it has extremely high affinity for pituitary GHRH receptors, strong specificity, almost no interference with the normal function of other hormone axes, and excellent biocompatibility. Researchers have described it as a "physiological key that precisely activates the growth hormone axis," gently regulating growth hormone secretion by awakening the pituitary gland's own function. Exogenous GH, on the other hand, is like a "forced supplementation of hormones," directly increasing GH levels but disrupting physiological pulsation rhythms and easily leading to metabolic disorders.

As a classic research peptide in the field of growth hormone axis regulation and metabolic intervention, Tesamorelin's research has progressed from cell experiments and animal models to clinical applications. In 2010, it received FDA approval and was marketed under the brand name Egrifta SV for the treatment of HIV-related lipodystrophy. Its effects in promoting GH secretion, reducing visceral fat, and improving metabolic disorders have been fully validated. It is widely used in research scenarios such as metabolic disease model construction, anti-aging mechanism research, and muscle atrophy intervention. It serves as a crucial bridge connecting basic growth hormone research with clinical metabolic disease treatment and is currently the only GHRH-type research peptide approved by the FDA with large-scale clinical data support.

Tesamorelin Peptide Structure: Amino Acid Sequence and Basic Information: Tesamorelin is a synthetic single-chain polypeptide composed of 44 natural L-amino acids. It is a structurally optimized analog of natural human GHRH (1-44), with CAS numbers 218949-48-5 (free state) and 901758-09-6 (salt form). Its molecular formula is C₂₂₁H₃₆₆N₇₂O₆₇S, and its molecular weight is approximately 5135.86 Da. The core structure contains the complete amino acid sequence of natural human GHRH (1-44). The key structural modification is the attachment of a trans-3-hexenoic acid group to an N-terminal tyrosine residue. There is no C-terminal amidation modification. It is prepared through chemical synthesis, exhibiting high purity and stable biological activity. Its tertiary structure is highly consistent with natural GHRH, ensuring efficient binding to the GHRH receptor.

Its precise and highly functional structural design, along with N-terminal modification and a complete sequence length, endows it with long-lasting and potent scientific advantages. The core structural highlights and advantages are as follows:
• Complete sequence length preservation and activity assurance: It fully preserves all 44 amino acid sequences of natural human GHRH (1-44), which, compared to truncated GHRH analogs (such as Sermorelin, which contains fragments 1-29), better matches the human physiological structure. It not only possesses complete receptor binding activity but also superior pharmacokinetic characteristics, allowing for more precise mimicking of the physiological function of natural GHRH. This ensures its efficient activation of pituitary GHRH receptors and stimulation of pulsatile GH secretion, which is the foundation for its core scientific role.

• N-terminal trans-3-hexenoic acid modification: This is the core modification for Tesamorelin to achieve long-lasting stability. Adding a hydrophobic trans-3-hexenoic acid group at the N-terminus creates steric hindrance, effectively shielding the cleavage sites of proteases such as DPP-4, significantly enhancing the peptide chain's resistance to enzymatic degradation, extending the in vivo half-life from several minutes in natural GHRH to 26-38 minutes. Simultaneously, it improves the peptide chain's lipid solubility, enhances cell membrane penetration, and increases bioavailability after subcutaneous injection (to 4%-7%), addressing the drawbacks of natural GHRH such as easy degradation, short duration of action, and the need for frequent dosing.

• Receptor Specificity Advantage: The optimized peptide chain structure exhibits affinity for pituitary GHRH receptors comparable to natural GHRH. It efficiently activates receptors via the Gsα-cAMP-PKA signaling pathway, specifically stimulating pulsatile secretion of endogenous GH. A single subcutaneous injection daily produces 3-4 GH secretion peaks, lasting 6-8 hours, mimicking the GH secretion pattern during deep sleep. Simultaneously, it has extremely low affinity for other hormone receptors (such as insulin and glucocorticoid receptors), barely interfering with the metabolic functions of insulin, cortisol, and other hormones, resulting in superior safety.

• Biocompatibility Advantage: As a humanized peptide, its amino acid sequence is highly homologous to natural human GHRH, exhibiting no immunogenicity and not triggering antibody reactions, demonstrating good long-term safety. The N-terminal modified group is non-toxic and can be metabolized and broken down normally by the body, without accumulation, further enhancing its safety and tolerability for research use.

This ingenious structural design makes Tesamorelin a highly efficient, long-acting, and highly targeted growth hormone-releasing peptide. It precisely binds to pituitary GHRH receptors, mimicking physiological GH secretion, while structural modification avoids the limitations of natural GHRH, exhibiting excellent biocompatibility and stability. When it binds to GHRH receptors on the surface of anterior pituitary cells that secrete GH, it rapidly initiates the GH secretion program, thereby mediating IGF-1 production through GH and exerting metabolic regulation, tissue repair, and neuroprotective effects. Researchers, in elucidating its mechanism of action, were amazed by the molecular design wisdom of this synthetic peptide—its "physiological mimicry and long-term stability."

To date, core research on Tesamorelin has covered cell experiments, animal models, and clinical applications. Its effects on GH secretion promotion, metabolic regulation, visceral fat reduction, and neuroprotection have been fully validated. It is widely used in research and clinical treatment of HIV-related lipodystrophy, obesity, metabolic syndrome, neurodegenerative diseases, and muscle atrophy. As the only FDA-approved GHRH peptide, its research value and clinical application potential are globally recognized, making it one of the most valuable research peptides in the field of growth hormone axis regulation and metabolic intervention.

Tesamorelin Peptide and Metabolic Regulation and Visceral Fat Reduction: The most core and extensive research value of Tesamorelin lies in its potent metabolic regulation and visceral fat reduction effects. It can exert precise intervention effects on metabolic disorders and visceral fat accumulation. Through a multi-target synergistic mechanism mediated by the GH-IGF-1 axis, it improves glucose and lipid metabolism, reduces visceral fat, and optimizes body composition, providing an important tool for research on HIV-related lipodystrophy, obesity, and metabolic syndrome. In clinical studies and animal models, its metabolic regulatory effects have shown significant advantages, especially in reducing visceral fat.

Its core metabolic regulation and visceral fat reduction mechanisms are clearly defined, with multiple targets working synergistically:

• Stimulates pulsatile GH secretion, mediating IGF-1 production: By activating pituitary GHRH receptors, it specifically stimulates the pulsatile secretion of endogenous GH. GH further acts on tissues such as the liver, promoting the synthesis and release of insulin-like growth factor-1 (IGF-1). Serum IGF-1 levels can increase by approximately 25% within 24 hours. As a major GH mediator, IGF-1 plays a core role in metabolic regulation, lipolysis, and protein synthesis, which is the basis for its metabolic effects.

• Effectively reduces visceral fat and optimizes body composition: It can significantly reduce visceral fat volume, especially abdominal visceral fat. In a 26-week phase III clinical trial, daily subcutaneous injection of Tesamorelin (2mg) reduced visceral fat by 15%-20% in patients with HIV-related lipodystrophy, with minimal impact on subcutaneous fat. Its mechanism involves activating lipolysis pathways within adipocytes, promoting the breakdown of visceral adipocytes, and simultaneously downregulating perilipin mRNA expression to reduce adipocyte volume, achieving a "fat reduction without muscle loss" research intervention effect. It is suitable for research on models related to visceral fat accumulation.

• Improves glucose and lipid metabolism and enhances insulin sensitivity: It promotes cellular glucose uptake and utilization, enhances insulin sensitivity, and helps regulate blood glucose levels, preventing drastic blood glucose fluctuations. Simultaneously, it improves lipid metabolism, reducing triglyceride and low-density lipoprotein levels while increasing high-density lipoprotein levels, alleviating lipid disorders associated with metabolic syndrome. In a diet-induced obesity (DIO) rat model, daily subcutaneous injection of Tesamorelin (0.5 mg/kg) for 4 weeks significantly improved glucose and lipid metabolism indicators in rats.

• Clinically validated metabolic improvement: In two phase III clinical trials involving 816 patients with HIV-related lipodystrophy, after 26 weeks of treatment with Tesamorelin (2 mg/day, subcutaneous injection), patients showed significant reductions in waist circumference and visceral fat area, along with improvements in blood lipid and blood glucose levels. The treatment was well-tolerated with no serious adverse reactions, providing strong support for its research value in metabolic regulation.

Studies have confirmed that Tesamorelin, at clinical research doses (1-2 mg/day, subcutaneous injection), significantly exerts its effects on metabolic regulation and visceral fat reduction. Its physiologically pulsatile GH secretion-promoting properties make it an ideal research tool in areas such as metabolic disorders and visceral fat accumulation, particularly suitable for long-term metabolic interventions and body composition optimization research.

Tesamorelin Peptides and Muscle Protection and Tissue Repair
In addition to metabolic regulation, Tesamorelin also possesses significant muscle protection and tissue repair functions. Its effects stem from the activation of the GH-IGF-1 axis, promoting muscle protein synthesis, inhibiting muscle breakdown, and accelerating tissue repair. This provides an important tool for research related to muscle atrophy, sarcopenia in the elderly, and tissue damage, and is particularly suitable for studies using aging models and injury repair models.

Its core muscle protection and tissue repair mechanisms and manifestations:

• Promotes muscle protein synthesis and maintains muscle mass: By activating the PI3K/Akt/mTOR signaling pathway through the GH-IGF-1 axis, it significantly promotes intracellular protein synthesis in muscle cells, increases the cross-sectional area of ​​muscle fibers, and simultaneously inhibits the ubiquitin-proteasome pathway, reducing muscle protein degradation. In an aged rat model, daily injection of Tesamorelin (1 mg/kg) for 8 weeks resulted in a 12% recovery of lean body mass and a significant increase in grip strength, effectively alleviating muscle loss associated with sarcopenia in the elderly.

• Accelerates tissue repair and promotes regeneration: It can promote the proliferation and differentiation of fibroblasts and skeletal muscle satellite cells, accelerate the repair of damage to tissues such as skin, muscle, and bone, and reduce tissue fibrosis. When used in combination with repair peptides such as BPC-157 and TB-500, it can produce a synergistic repair effect, further improving the efficiency of damage repair, making it suitable for research scenarios such as muscle injury, fracture, and skin wound repair.

• Improves muscle function and enhances athletic performance: In muscle atrophy models, Tesamorelin significantly improves muscle contraction function, enhances muscle endurance and athletic performance. Its mechanism is related to promoting muscle fiber regeneration and increasing muscle mass, while also relieving muscle soreness and fatigue, making it suitable for research related to muscle function decline.

• Anti-aging-related muscle protection effects: With age, the levels of GH and IGF-1 in the human body gradually decline, leading to reduced muscle mass and decreased muscle function. Tesamorelin, by stimulating endogenous GH secretion, can delay muscle loss in the elderly and maintain muscle function, providing an important tool for anti-aging-related muscle protection research. It can also improve body composition and quality of life in the elderly.

Furthermore, the long-acting nature of Tesamorelin allows for once-daily dosing to maintain continuous muscle protection and tissue repair effects, avoiding the interference of frequent dosing on experimental models. Moreover, by activating endogenous GH secretion, it more closely reflects the human physiological state, making research results more valuable. This characteristic makes it suitable for long-term research observation scenarios related to muscle protection and tissue repair.

Tesamorelin Peptide and Neuroprotection and Anti-aging

Tesamorelin is an important molecule connecting growth hormone axis regulation with neuroprotection and anti-aging. Its effects stem not only from metabolic regulation and muscle protection but also from activating the GH-IGF-1 axis, protecting neurons, improving cognitive function, and delaying the aging process. This provides new insights for research on neurodegenerative diseases and anti-aging. Furthermore, its effects are mild and its safety profile is superior to exogenous GH administration.

Its neuroprotective and anti-aging mechanisms:

• Neuroprotective effects: It can upregulate the expression of brain-derived neurotrophic factor (BDNF) in the hippocampus through the GH-IGF-1 axis, promoting neuronal proliferation and differentiation, protecting neurons from oxidative stress and ischemic hypoxia damage, and improving synaptic plasticity. In the Morris water maze test in aged rats, the cognitive performance of rats treated with Tesamorelin improved by 25%, which was closely related to the increased BDNF levels in the hippocampus. This makes it suitable for research in models of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.

• Improves cognitive function and slows cognitive decline: By activating the GH-IGF-1 axis, it optimizes cerebral blood circulation, enhances neuronal energy metabolism, improves memory, attention, and executive function, and alleviates age-related cognitive decline. Simultaneously, it reduces the release of inflammatory factors in the brain, inhibits neuroinflammation, and maintains cerebral homeostasis, providing an important tool for research related to cognitive decline.

• Anti-aging effects: By stimulating the secretion of endogenous GH and IGF-1, it regulates metabolism, reduces oxidative stress damage, and slows cellular aging. It can improve skin elasticity, reduce wrinkle formation, maintain muscle mass, improve bone density, and comprehensively delay the aging process, making it suitable for research on anti-aging mechanisms and the construction of aging models.

• Liver protective effects: It can upregulate the expression of genes related to oxidative phosphorylation in liver tissue, downregulate the expression of genes in inflammation and fibrosis pathways, and improve hepatic steatosis associated with non-alcoholic fatty liver disease.

In clinical studies, some patients experienced a decrease in serum alanine aminotransferase (ALT) levels after treatment, suggesting a certain protective effect on the liver and making it suitable for research on liver metabolic diseases.

Animal experiments and clinical studies have confirmed that Tesamorelin can significantly exert neuroprotective and anti-aging effects. Its triple characteristics of "metabolic regulation + neuroprotection + anti-aging" make it an ideal tool for multidimensional scientific research, especially suitable for research on the intersection of growth hormone axis regulation and neuro-anti-aging.

Tesamorelin Peptide and Safety: As a structurally optimized analogue of natural GHRH, Tesamorelin has demonstrated excellent safety in large-scale clinical studies and scientific applications, with few and mild adverse reactions. Core risks are related to dosage, administration method, and specific populations, requiring strict limitation to research settings. Furthermore, caution should be exercised regarding the purity and structural deviations of products from unofficial channels. Its safety data comes from clinical trials involving over 800 patients, making it one of the GHRH peptides with the most robust safety evidence currently available.

• Common Reactions: Local reactions are the most common. During subcutaneous injection, approximately 30%-51% of research models experience mild redness, swelling, itching, pain, or induration at the injection site. These are mostly transient reactions and can be effectively relieved by rotating injection sites (abdomen, thigh, upper arm). They usually subside completely within 24-48 hours after discontinuation of the drug. In addition, joint pain, muscle pain, peripheral edema, finger swelling, or carpal tunnel syndrome-like numbness may occur, often related to excessive dosage or a transient increase in GH levels. These symptoms can be quickly relieved by reducing the dosage.

• Potential risks: High-dose use (>2 mg/day) may lead to a sustained increase in IGF-1 levels, requiring regular monitoring. If a sustained increase (>3 standard deviations) occurs, discontinuation of the drug should be considered. Long-term continuous use (>26 weeks) may lead to visceral fat rebound. Studies show that 52 weeks after discontinuation, patients may recover 24.5% of their visceral fat, suggesting the need for long-term continuous intervention. When used in models with active tumors, it may promote tumor proliferation; it is necessary to ensure the tumor is in a quiescent phase and that treatment is completed before use. When used in models of diabetes or impaired glucose tolerance, elevated blood glucose may occur, requiring close monitoring of blood glucose levels and adjustment of hypoglycemic drug dosage if necessary.

• Drug Interactions: When used in combination with insulin or oral hypoglycemic agents, GH may antagonize the hypoglycemic effect of insulin, potentially leading to elevated blood glucose levels. Adjustments to the hypoglycemic agent dosage and close monitoring of blood glucose are necessary. When used in combination with glucocorticoids, GH secretion may be weakened, requiring adjustment of the Tesamorelin dosage. When used in combination with drugs metabolized by CYP450 enzymes, such as cyclosporine, sex hormones, and antiepileptic drugs, GH may affect drug clearance, necessitating monitoring of drug concentration and clinical response. When used in combination with antiretroviral drugs, no significant adverse interactions are observed, making it suitable for HIV-related model studies.

• Important Reminder: Tesamorelin is only approved in some countries for the clinical treatment of HIV-related lipodystrophy. Research use must be strictly limited to laboratory analysis, cell experiments, and animal model studies. It is strictly prohibited for use in models with pituitary tumors, a history of pituitary surgery, a history of head radiotherapy, active tumors, allergies to Tesamorelin or mannitol, pregnant women, and lactating women. Use is not recommended for adolescent models under 18 years of age due to insufficient safety data. Products from unofficial channels may have insufficient purity, peptide chain degradation, structural deviations, etc., seriously affecting research safety and experimental reproducibility. After reconstitution, it must be stored at 4°C and used within 7 days to avoid peptide chain degradation affecting activity.

Overall, Tesamorelin is well tolerated at standard research doses (1-2 mg/day, subcutaneous injection), with most side effects being mild and reversible. Its physiologically pulsatile GH secretion-stimulating properties make it safer than exogenous GH administration, making it a safe and reliable research tool in areas such as growth hormone axis regulation, metabolic intervention, and neuroprotection. However, its use in specific populations and research models requires strict contraindications. Furthermore, strict control over product sourcing and purity is essential. A research cycle of 12-26 weeks is recommended, with a 2-4 week interval between cycles if necessary.

Future Research and Clinical Trials of Tesamorelin

Tesamorelin, a multifunctional growth hormone-releasing peptide, continues to expand its research boundaries. Multiple cell experiments, animal studies, and clinical trials have been conducted, and its clinical applications are constantly expanding. Its scientific value in multiple fields continues to be explored. Core research directions revolve around metabolic regulation mechanisms, indication expansion, dosage form optimization, and long-term safety validation:

• Completed Studies: Cell and animal experiments on GH secretion mechanisms (GHRH receptor activation, GH pulsatile secretion regulation), metabolic regulation and visceral fat reduction, muscle protection and tissue repair, neuroprotection and anti-aging effects; two Phase III clinical trials have confirmed its therapeutic efficacy and safety in HIV-related lipodystrophy, and it received FDA approval in 2010; studies on its synergistic effects with other peptides have been completed, providing a foundation for combination drug research; studies on its pharmacokinetics, metabolic pathways, and structure-activity relationships have also been completed, providing support for dosage form optimization and derivative development.

• Ongoing Research: In-depth studies of Tesamorelin in common obesity, metabolic syndrome, and non-alcoholic fatty liver disease; dosage form optimization, development of long-acting sustained-release formulations to prolong duration of action and reduce dosing frequency; development of its derivatives to further improve stability, bioavailability, and targeting; long-term safety monitoring to improve safety data for special populations such as the elderly and diabetic patients; and preclinical studies in neurodegenerative diseases and sarcopenia to expand the scope of research indications.

• Cutting-Edge Research: Synergistic metabolic regulation studies of Tesamorelin in combination with GLP-1 receptor agonists to explore its combined research value in obesity and diabetes; synergistic effects of combining it with stem cell technology to explore its effects on tissue regeneration; development of oral dosage forms to overcome the limitations of administration methods and expand research application scenarios; exploration of its potential value in pain regulation and sleep disorders; exploration of its synergistic regulatory mechanism on the growth hormone axis and neuroimmune network, providing new directions for interdisciplinary research on neurodegenerative and metabolic diseases; and optimization of its application in serum-free cell culture to improve recombinant protein expression efficiency.

Current research focuses on expanding its research indications, optimizing dosage forms and usage regimens, and improving safety data for specific populations. Simultaneously, it explores its synergistic effects with other drugs and peptides, providing more precise and efficient tools for precision research and novel drug development in areas such as growth hormone axis regulation, metabolic disorders, neuroprotection, and anti-aging, thereby driving scientific breakthroughs in related fields.

Our Tesamorelin has the following significant characteristics:

• Guaranteed purity: Each batch of product undergoes dual testing by HPLC and mass spectrometry, with a purity ≥99%. Verified by an independent third-party laboratory, it is free from bacterial contamination, impurities, oxidation products, and peptide degradation fragments, ensuring the accuracy and reliability of research data. It is a white to off-white loose lyophilized powder, readily soluble in sterile water, PBS, and physiological saline. The aqueous solution is clear, consistent with the typical physicochemical characteristics of Tesamorelin. Its pH range is 4.0-7.5, suitable for scientific experiments and cell culture under physiological conditions.

• Precise Dosage: 5 mg vials, suitable for research dosage requirements. Different concentrations can be flexibly configured according to experimental protocols (e.g., 10-100 nM for cell experiments, 1-2 mg/day for in vivo experiments), avoiding dosage waste. Meets various research scenarios such as cell experiments, animal models, combination drug studies, and metabolic intervention experiments. Adapts to commonly used clinical research dosage ranges, enabling dose gradient studies.

• High Stability: Lyophilized powder formulation, strictly adhering to GMP-grade production standards. Can be stored long-term (≥2 years) under dry, light-protected, and sealed conditions at -20℃. N-terminal trans-3-hexenoic acid modification effectively protects the peptide chain from enzymatic degradation, maintaining activity. Stable for 7 days at 4℃ after reconstitution and 24 hours at room temperature after reconstitution. Suitable for global laboratory transportation and storage conditions, requiring no special antioxidant treatment, facilitating research use. Detailed reconstitution guidelines are provided, specifying that the concentration after reconstitution in 2 ml of antibacterial water is 2.5 mg/ml, facilitating precise dosage extraction.

• Structural Purity: Utilizing standard chemical synthesis processes, the amino acid sequence of Tesamorelin (44 amino acids, including N-terminal trans-3-hexenoic acid modification) is precisely replicated, completely preserving the core structure and active motif of natural GHRH (1-44), without any artificial terminal modification deviations. This ensures its binding activity to the GHRH receptor and its physiological pulsatile GH secretion-promoting efficacy, completely consistent with the FDA-approved clinical formulation sequence, guaranteeing experimental reproducibility.

• Research Use Only: Clearly labeled "For Research Use Only," strictly limited to cell experiments, animal models, and research on growth hormone axis regulation, metabolic regulation, neuroprotection, and anti-aging mechanisms. Non-research use is strictly prohibited. Complete quality control reports, reconstitution guidelines, and storage instructions are provided, reminding users to accurately prepare the concentration according to the administration method, regularly monitor IGF-1 levels and blood glucose, rotate injection sites, and pay attention to storage conditions to avoid peptide degradation affecting experimental results.

For researchers exploring the mechanisms of growth hormone axis regulation, metabolic disorders, muscle protection, neuroprotection, and anti-aging, Tesamorelin is undoubtedly a key tool molecule for unlocking the physiological functions and metabolic regulatory potential of growth hormone and promoting breakthroughs in multiple fields of research. Its physiologically pulsatile secretion, long-term stability, and high safety make it one of the most valuable research peptides in the field of growth hormone axis regulation and metabolic intervention, and it is widely used in scientific research exploration in life sciences, pharmaceutical development, anti-aging research, and other related fields.